EXACT Sciences Corporation Stock News

ResMed's (RMD) adjusted gross margin improves on benefits from changes in product mix, and manufacturing and procurement efficiencies.

Stryker's (SYK) first-quarter earnings gain from strong performance at MedSurg and Neurotechnology and Spine units.

Cwm LLC increased its stake in EXACT Sciences Co. (NASDAQ:EXAS) by 26.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. Th

As of late, it has definitely been a great time to be an investor in Exact Sciences.

Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.

QIAGEN (QGEN) is expected to have gained from increased adoption of testing solutions to identify the SARS-CoV-2 in Q1 amid the coronavirus pandemic.

QIAGEN (QGEN) is expected to have gained from increased adoption of testing solutions to identify the SARS-CoV-2 in Q1 amid the coronavirus pandemic.

ABIOMED's (ABMD) flagship Impella saw decline in revenues within United States in Q4.

Baxter's (BAX) first-quarter earnings benefit from solid segmental performance and growth across all geographies.

Baxter's (BAX) first-quarter earnings benefit from solid segmental performance and growth across all geographies.

Capital Investment Advisory Services LLC lessened its holdings in EXACT Sciences Co. (NASDAQ:EXAS) by 20.6% during the 1st quarter, according to the company in its most recent 13F filing with the Secu

During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease

During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.